PETCM |
| Catalog No.GC14886 |
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 10129-56-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
PETCM is an activator of caspase-3 [1].
Caspase-3 is a member of the cysteine-aspartic acid protease family and interacts with caspase-8 and caspase-9. Sequential activation of caspases plays an important role in cell apoptosis.
In HeLa S-100 cell cytosol, PETCM activated caspase-3 in a dose-dependent way and induced apoptosome formation. PETCM (0.2 mM) caused Apaf-1 shifted to a size of ~1 million daltons, which indicating apoptosome formation. Also, PETCM function required dATP. The activation effect of PETCM on caspase-3 was independent of PHAP proteins. When inhibited the activation activity of the PHAP proteins, PETCM reversed the suppression. When added to Q30 (Apaf-1/procaspase-9) plus cytochrome c and 10 μM dATP, recombinant PHAPI activated caspase-3. The activity was inhibited by recombinant ProT. While, PETCM reversed the inhibitory effect of ProT. PHAPI didn’t affect apoptosome formation and activated caspase-9 and Apaf-1, which were associated with apoptosome. ProT efficiently blocked formation of apoptosome and PETCM relieved this effect [1].
Reference:
[1]. Jiang X, Kim HE, Shu H, et al. Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway. Science, 2003, 299(5604): 223-226.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *